Stem definition | Drug id | CAS RN |
---|---|---|
quaternary ammonium compounds | 2489 | 306-40-1 |
None
Property | Value | Reference |
---|---|---|
BA (Bioavailability) | 0 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
Aug. 20, 1952 | FDA | SANDOZ |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Anaphylactic shock | 433.98 | 36.23 | 131 | 4030 | 20143 | 46661758 |
Cardiac arrest | 186.85 | 36.23 | 110 | 4051 | 90289 | 46591612 |
Hyperthermia malignant | 184.39 | 36.23 | 35 | 4126 | 714 | 46681187 |
Hypotension | 181.82 | 36.23 | 156 | 4005 | 232433 | 46449468 |
Exposure during pregnancy | 163.72 | 36.23 | 108 | 4053 | 108104 | 46573797 |
Diabetes insipidus | 152.44 | 36.23 | 36 | 4125 | 2138 | 46679763 |
Anaphylactic reaction | 134.77 | 36.23 | 74 | 4087 | 53038 | 46628863 |
Bronchospasm | 134.06 | 36.23 | 51 | 4110 | 15656 | 46666245 |
Maternal exposure during pregnancy | 116.64 | 36.23 | 86 | 4075 | 102463 | 46579438 |
Renal ischaemia | 116.48 | 36.23 | 23 | 4138 | 580 | 46681321 |
PCO2 increased | 110.44 | 36.23 | 25 | 4136 | 1229 | 46680672 |
PO2 increased | 96.29 | 36.23 | 21 | 4140 | 869 | 46681032 |
Foetal death | 87.78 | 36.23 | 32 | 4129 | 8711 | 46673190 |
Blood pH decreased | 87.42 | 36.23 | 24 | 4137 | 2603 | 46679298 |
Oxygen saturation abnormal | 86.61 | 36.23 | 24 | 4137 | 2694 | 46679207 |
Blood bicarbonate decreased | 80.67 | 36.23 | 23 | 4138 | 2862 | 46679039 |
Neuromuscular block prolonged | 76.81 | 36.23 | 16 | 4145 | 530 | 46681371 |
Ventricular tachycardia | 76.61 | 36.23 | 35 | 4126 | 16932 | 46664969 |
Delayed recovery from anaesthesia | 74.92 | 36.23 | 17 | 4144 | 844 | 46681057 |
Rhabdomyolysis | 73.45 | 36.23 | 46 | 4115 | 41863 | 46640038 |
Left ventricular dysfunction | 72.27 | 36.23 | 29 | 4132 | 10226 | 46671675 |
Bradycardia | 71.66 | 36.23 | 54 | 4107 | 66244 | 46615657 |
Foetal exposure during pregnancy | 67.46 | 36.23 | 39 | 4122 | 30708 | 46651193 |
Pulseless electrical activity | 67.39 | 36.23 | 25 | 4136 | 7142 | 46674759 |
Apnoea | 59.59 | 36.23 | 23 | 4138 | 7316 | 46674585 |
Status epilepticus | 57.38 | 36.23 | 27 | 4134 | 13952 | 46667949 |
Drug interaction | 54.47 | 36.23 | 78 | 4083 | 203016 | 46478885 |
Anaesthetic complication | 53.12 | 36.23 | 15 | 4146 | 1802 | 46680099 |
Renal impairment | 51.89 | 36.23 | 47 | 4114 | 74325 | 46607576 |
Premature baby | 50.75 | 36.23 | 27 | 4134 | 18085 | 46663816 |
Blood magnesium decreased | 50.63 | 36.23 | 23 | 4138 | 10969 | 46670932 |
Electroencephalogram abnormal | 50.15 | 36.23 | 17 | 4144 | 3737 | 46678164 |
Patent ductus arteriosus | 49.67 | 36.23 | 17 | 4144 | 3845 | 46678056 |
Kounis syndrome | 49.51 | 36.23 | 13 | 4148 | 1189 | 46680712 |
Encephalopathy | 46.91 | 36.23 | 32 | 4129 | 33557 | 46648344 |
Ventricular fibrillation | 46.55 | 36.23 | 22 | 4139 | 11474 | 46670427 |
Clonus | 44.94 | 36.23 | 16 | 4145 | 4064 | 46677837 |
Hyperkalaemia | 43.34 | 36.23 | 36 | 4125 | 50673 | 46631228 |
Blood calcium decreased | 42.88 | 36.23 | 23 | 4138 | 15650 | 46666251 |
Maternal exposure during delivery | 39.32 | 36.23 | 10 | 4151 | 806 | 46681095 |
Diarrhoea | 38.71 | 36.23 | 3 | 4158 | 559599 | 46122302 |
Seizure | 38.54 | 36.23 | 51 | 4110 | 123003 | 46558898 |
Unresponsive to stimuli | 36.48 | 36.23 | 27 | 4134 | 32147 | 46649754 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Hyperthermia malignant | 335.27 | 34.29 | 68 | 2925 | 1766 | 29947719 |
Anaphylactic shock | 238.06 | 34.29 | 78 | 2915 | 13915 | 29935570 |
Anaphylactic reaction | 146.12 | 34.29 | 66 | 2927 | 27916 | 29921569 |
Serotonin syndrome | 139.17 | 34.29 | 56 | 2937 | 17835 | 29931650 |
Cardiac arrest | 104.66 | 34.29 | 81 | 2912 | 92769 | 29856716 |
Bronchospasm | 75.63 | 34.29 | 31 | 2962 | 10307 | 29939178 |
Anaesthetic complication | 69.34 | 34.29 | 17 | 2976 | 1052 | 29948433 |
Rhabdomyolysis | 68.30 | 34.29 | 54 | 2939 | 63526 | 29885959 |
Procedural hypotension | 64.96 | 34.29 | 16 | 2977 | 1009 | 29948476 |
Seizure like phenomena | 58.14 | 34.29 | 13 | 2980 | 537 | 29948948 |
Pseudocholinesterase deficiency | 54.87 | 34.29 | 8 | 2985 | 23 | 29949462 |
Neuromuscular block prolonged | 51.74 | 34.29 | 11 | 2982 | 358 | 29949127 |
Metabolic acidosis | 51.69 | 34.29 | 37 | 2956 | 37424 | 29912061 |
Hypotension | 51.39 | 34.29 | 80 | 2913 | 200485 | 29749000 |
Ventricular tachycardia | 51.04 | 34.29 | 31 | 2962 | 23831 | 29925654 |
Blood creatine phosphokinase increased | 48.66 | 34.29 | 38 | 2955 | 43810 | 29905675 |
Muscle rigidity | 46.55 | 34.29 | 22 | 2971 | 10239 | 29939246 |
Apnoea | 43.15 | 34.29 | 18 | 2975 | 6240 | 29943245 |
Pseudomonal sepsis | 40.14 | 34.29 | 14 | 2979 | 2986 | 29946499 |
Methaemoglobinaemia | 38.60 | 34.29 | 13 | 2980 | 2497 | 29946988 |
Drug interaction | 34.51 | 34.29 | 67 | 2926 | 199501 | 29749984 |
Source | Code | Description |
---|---|---|
ATC | M03AB01 | MUSCULO-SKELETAL SYSTEM MUSCLE RELAXANTS MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS Choline derivatives |
FDA EPC | N0000175719 | Depolarizing Neuromuscular Blocker |
FDA PE | N0000175733 | Neuromuscular Depolarizing Blockade |
MeSH PA | D009465 | Neuromuscular Agents |
MeSH PA | D009466 | Neuromuscular Blocking Agents |
MeSH PA | D009467 | Neuromuscular Depolarizing Agents |
MeSH PA | D018373 | Peripheral Nervous System Agents |
CHEBI has role | CHEBI:51371 | muscle relaxants |
CHEBI has role | CHEBI:88188 | allergenic drug |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Muscle relaxation, function | indication | 11977004 | |
General anesthesia | indication | 50697003 | |
Skeletal Muscle Relaxation for Endotracheal Intubation | indication | ||
Ocular hypertension | contraindication | 4210003 | DOID:9282 |
Hypocalcemia | contraindication | 5291005 | |
Poisoning by digitalis glycoside | contraindication | 12876009 | |
Hyperkalemia | contraindication | 14140009 | |
Glaucoma | contraindication | 23986001 | DOID:1686 |
Infectious disease | contraindication | 40733004 | |
Myxedema | contraindication | 43153006 | DOID:11634 |
Hypokalemia | contraindication | 43339004 | |
Burn injury | contraindication | 48333001 | |
Bradycardia | contraindication | 48867003 | |
Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
Acute nephropathy | contraindication | 58574008 | |
Hepatic failure | contraindication | 59927004 | |
Muscular dystrophy | contraindication | 73297009 | DOID:9884 |
Duchenne muscular dystrophy | contraindication | 76670001 | DOID:11723 |
Third degree burn injury | contraindication | 80247002 | |
Spinal cord injury | contraindication | 90584004 | |
Myasthenia gravis | contraindication | 91637004 | DOID:437 |
Fracture of bone | contraindication | 125605004 | |
Disorder of muscle | contraindication | 129565002 | DOID:423 |
Spasticity | contraindication | 221360009 | |
Rhabdomyolysis | contraindication | 240131006 | |
Anemia | contraindication | 271737000 | DOID:2355 |
Injury of eye region | contraindication | 282752000 | |
Deficiency of cholinesterase | contraindication | 360607009 | |
At risk for aspiration | contraindication | 371736008 | |
Primary malignant neoplasm | contraindication | 372087000 | |
Surgical procedure on eye proper | contraindication | 373353005 | |
Fever | contraindication | 386661006 | |
Angle-closure glaucoma | contraindication | 392291006 | DOID:13550 |
Malignant hyperthermia | contraindication | 405501007 | |
Cardiac arrest | contraindication | 410429000 | DOID:0060319 |
Traumatic injury | contraindication | 417746004 | |
Cardiac Decompensation | contraindication |
None
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Muscle-type nicotinic acetylcholine receptor | Ion channel | AGONIST | CHEMBL | CHEMBL | |||||
Acetylcholinesterase | Enzyme | Ki | 4.68 | CHEMBL |
ID | Source |
---|---|
4017730 | VUID |
N0000178917 | NUI |
D00766 | KEGG_DRUG |
71-27-2 | SECONDARY_CAS_RN |
4017730 | VANDF |
4019935 | VANDF |
C0038627 | UMLSCUI |
CHEBI:45652 | CHEBI |
SCK | PDB_CHEM_ID |
CHEMBL703 | ChEMBL_ID |
CHEMBL983 | ChEMBL_ID |
DB00202 | DRUGBANK_ID |
D013390 | MESH_DESCRIPTOR_UI |
5314 | PUBCHEM_CID |
4004 | IUPHAR_LIGAND_ID |
26 | INN_ID |
J2R869A8YF | UNII |
10154 | RXNORM |
1940 | MMSL |
5517 | MMSL |
d00376 | MMSL |
001676 | NDDF |
005590 | NDDF |
372724004 | SNOMEDCT_US |
3822002 | SNOMEDCT_US |
58907007 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
QUELICIN | Human prescription drug label | 1 | 0409-6629 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | NDA | 13 sections |
QUELICIN | Human prescription drug label | 1 | 0409-6629 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | NDA | 13 sections |
QUELICIN | Human prescription drug label | 1 | 0409-6629 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | NDA | 13 sections |
QUELICIN | Human prescription drug label | 1 | 0409-6970 | INJECTION, SOLUTION | 100 mg | INTRAMUSCULAR | NDA | 13 sections |
QUELICIN | Human prescription drug label | 1 | 0409-6970 | INJECTION, SOLUTION | 100 mg | INTRAMUSCULAR | NDA | 13 sections |
Anectine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-3009 | INJECTION, SOLUTION | 20 mg | INTRAVENOUS | NDA | 23 sections |
Anectine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-3411 | INJECTION, SOLUTION | 20 mg | INTRAVENOUS | NDA | 20 sections |
Anectine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-9053 | INJECTION, SOLUTION | 20 mg | INTRAVENOUS | NDA | 20 sections |
Succinylcholine Chloride | Human Prescription Drug Label | 1 | 14445-407 | INJECTION | 20 mg | INTRAVENOUS | ANDA | 22 sections |
Succinylcholine Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 14789-104 | INJECTION | 20 mg | INTRAVENOUS | ANDA | 21 sections |
Succinylcholine Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-493 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 13 sections |
Succinylcholine Chloride | Human Prescription Drug Label | 1 | 31722-981 | INJECTION, SOLUTION | 20 mg | INTRAVENOUS | ANDA | 21 sections |
Succinylcholine Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42571-371 | INJECTION | 200 mg | INTRAMUSCULAR | ANDA | 21 sections |
Succinylcholine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-666 | INJECTION, SOLUTION | 20 mg | INTRAVENOUS | ANDA | 20 sections |
Succinylcholine Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49396-0152 | INJECTION | 200 mg | PARENTERAL | ANDA | 2 sections |
SUCCINYLCHOLINE CHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51662-1353 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | NDA | 13 sections |
SUCCINYLCHOLINE CHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51662-1525 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 12 sections |
SUCCINYLCHOLINE CHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51662-1526 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 13 sections |
SUCCINYLCHOLINE CHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51991-964 | INJECTION, SOLUTION | 20 mg | INTRAVENOUS | ANDA | 22 sections |
SUCCINYLCHOLINE CHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52584-097 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 12 sections |
Succinylcholine Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52584-964 | INJECTION, SOLUTION | 20 mg | INTRAVENOUS | ANDA | 13 sections |
Succinylcholine Chloride | Human prescription drug label | 1 | 52817-734 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 22 sections |
Succinylcholine Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54879-037 | INJECTION | 20 mg | INTRAVENOUS | ANDA | 22 sections |
SUCCINYLCHOLINE CHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-943 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 22 sections |
Succinylcholine Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66794-232 | INJECTION, SOLUTION | 20 mg | INTRAVENOUS | ANDA | 13 sections |
SUCCINYLCHOLINE CHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68001-448 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 20 sections |
Succinylcholine Chloride | Human Prescription Drug Label | 1 | 68083-450 | INJECTION, SOLUTION | 20 mg | INTRAVENOUS | ANDA | 12 sections |
Succinylcholine Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69918-700 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 20 sections |
Succinylcholine Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69918-700 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 20 sections |
Succinylcholine Chloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70069-301 | INJECTION, SOLUTION | 20 mg | INTRAMUSCULAR | ANDA | 12 sections |